GlobalData on MSN4mon
MSD’s Phase III trial of head and neck cancer treatment meets primary endpoint
MSD (Merck & Co.) has reported that the Phase III KEYNOTE-689 trial of its KEYTRUDA (pembrolizumab) for the treatment of head ...
GlobalData on MSN3mon
Moderna and MSD begin trial of mRNA-4157 and Keytruda combination for lung cancer
Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised ...
pharmaphorum3d
MSD gets first positive trial of Keytruda/Lynparza combo
MSD's efforts to combine cancer immunotherapy Keytruda with its AstraZeneca-partnered PARP drug Lynparza have so far failed – but at last it can point to a partial win in a phase 3 trial.
pharmaphorum1d
MSD hits a hurdle with its LAG-3 programme
MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable (MSS ...